|
1
|
Van Cutsem E, Cervantes A, Nordlinger B
and Arnold D; ESMO Guidelines Working Group, : Metastatic
colorectal cancer: ESMO clinical practice guidelines for diagnosis,
treatment and follow-up. Ann Oncol. 25 Suppl 3:iii1–iii9. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Benson AB III, Venook AP, Bekaii-Saab T,
Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ,
Fuchs CS, et al: Colon cancer, version 3.2014. J Natl Compr Canc
Netw. 12:1028–1059. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Van Cutsem E, Köhne CH, Láng I, Folprecht
G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D,
Tejpar S, et al: Cetuximab plus irinotecan, fluorouracil, and
leucovorin as first-line treatment for metastatic colorectal
cancer: Updated analysis of overall survival according to tumor
KRAS and BRAF mutation status. J Clin Oncol. 29:2011–2019. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Grothey A, Van Cutsem E, Sobrero A, Siena
S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, et
al: Regorafenib monotherapy for previously treated metastatic
colorectal cancer (CORRECT): An international, multicentre,
randomised, placebo-controlled, phase 3 trial. Lancet. 381:303–312.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mayer RJ, Van Cutsem E, Falcone A, Yoshino
T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero
J, Komatsu Y, et al: Randomized trial of TAS-102 for refractory
metastatic colorectal cancer. N Engl J Med. 372:1909–1919. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Nielsen DL, Palshof JA, Larsen FO, Jensen
BV and Pfeiffer P: A systematic review of salvage therapy to
patients with metastatic colorectal cancer previously treated with
fluorouracil, oxaliplatin and irinotecan +/− targeted therapy.
Cancer Treat Rev. 40:701–715. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Scartozzi M, Falcone A, Pucci F, Braconi
C, Pierantoni C, Cavanna L, Franciosi V, Berardi R, Beretta G, Masi
G, et al: Capecitabine and mitomycin C may be an effective
treatment option for third-line chemotherapy in advanced colorectal
cancer. Tumori. 92:384–388. 2006.PubMed/NCBI
|
|
8
|
Vormittag L, Kornek GV, Gruhsmann B,
Lenauer A, Föger A, Depisch D, Lang F and Scheithauer W:
UFT/leucovorin and mitomycin C as salvage treatment in patients
with advanced colorectal cancer-a retrospective analysis.
Anticancer Drugs. 18:709–712. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gubanski M, Naucler G, Almerud A,
Lideståhl A and Lind PA: Capecitabine as third line therapy in
patients with advanced colorectal cancer. Acta Oncol. 44:236–239.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lee S, Kwon HC, Kim SHOHYS, Lee HJ, Yoon
HH, Choi JH and Kim JH: Capecitabine monotherapy, and the clinical
significance of neutrophil-lymphocyte ratio versus
platelet-lymphocyte ratio in patients with metastatic colorectal
cancer. ASCO Annual Meeting Proceedings. pp. 6602012;
|
|
11
|
Jeung HC, Rha SY, Cho BC, Yoo NC, Roh JK,
Roh WJ, Chung HC and Ahn JB: A phase II trial of S-1 monotherapy in
metastatic colorectal cancer after failure of irinotecan- and
oxaliplatin-containing regimens. Br J Cancer. 95:1637–1641. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sun Jin Sym, Junshik Hong, Hee Kyung Ahn,
Jinny Park, Eun Kyung Cho, Jae Hoon Lee, Won-Suk Lee, Jeong-Heum
Baek, Ho Park Yeon, Bok Shin Dong, et al: A phase II trial of
salvage treatment with gemcitabine and S-1 combination in heavily
pretreated patients with metastatic colorectal cancer. J Clin
Oncol. 31 Suppl 4:S4882013. View Article : Google Scholar
|
|
13
|
Santini D, Vincenzi B, La Cesa A, Caricato
M, Schiavon G, Spalletta B, Di Seri M, Coppola R, Rocci L and
Tonini G: Continuous infusion of oxaliplatin plus chronomodulated
capecitabine in 5-fluorouracil- and irinotecan-resistant advanced
colorectal cancer patients. Oncology. 69:27–34. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Townsend AR, Bishnoi S, Broadbridge V,
Beeke C, Karapetis CS, Jain K, Luke C, Padbury R and Price TJ:
Rechallenge with oxaliplatin and fluoropyrimidine for metastatic
colorectal carcinoma after prior therapy. Am J Clin Oncol.
36:49–52. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Grothey A, Hedrick EE, Mass RD, Sarkar S,
Suzuki S, Ramanathan RK, Hurwitz HI, Goldberg RM and Sargent DJ:
Response-independent survival benefit in metastatic colorectal
cancer: A comparative analysis of N9741 and AVF2107. J Clin Oncol.
26:183–189. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Buyse M, Thirion P, Carlson RW,
Burzykowski T, Molenberghs G and Piedbois P: Relation between
tumour response to first-line chemotherapy and survival in advanced
colorectal cancer: A meta-analysis. Meta-analysis group in cancer.
Lancet. 356:373–378. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Piessevaux H, Buyse M, Schlichting M, Van
Cutsem E, Bokemeyer C, Heeger S and Tejpar S: Use of early tumor
shrinkage to predict long-term outcome in metastatic colorectal
cancer treated with cetuximab. J Clin Oncol. 31:3764–3775. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cremolini C, Loupakis F, Antoniotti C,
Lonardi S, Masi G, Salvatore L, Cortesi E, Tomasello G, Spadi R,
Zaniboni A, et al: Early tumor shrinkage and depth of response
predict long-term outcome in metastatic colorectal cancer patients
treated with first-line chemotherapy plus bevacizumab: Results from
phase III TRIBE trial by the Gruppo Oncologico del Nord Ovest. Ann
Oncol. 26:1188–1194. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ettinger DS, Wood DE, Akerley W, Bazhenova
LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA,
Demmy TL, et al: Non-small cell lung cancer, version 6.2015. J Natl
Compr Canc Netw. 13:515–524. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Horie N, Aiba H, Oguro K, Hojo H and
Takeishi K: Functional analysis and DNA polymorphism of the
tandemly repeated sequences in the 5′-terminal regulatory region of
the human gene for thymidylate synthase. Cell Struct Funct.
20:191–197. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee DJ, Lee J, Lee HY, Lim T, Lee SJ, Yi
SY, Park SH, Park JO, Lim HY, Kang WK and Park YS: Salvage S-1
monotherapy in metastatic colorectal cancer patients who failed
irinotecan-based or oxaliplatin-based chemotherapy. Med Oncol. 28
Suppl 1:S291–S294. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cremolini C, Loupakis F, Antoniotti C,
Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M,
Zaniboni A, et al: FOLFOXIRI plus bevacizumab versus FOLFIRI plus
bevacizumab as first-line treatment of patients with metastatic
colorectal cancer: Updated overall survival and molecular subgroup
analyses of the open-label, phase 3 TRIBE study. Lancet Oncol.
16:1306–1315. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Etienne-Grimaldi MC, Milano G,
Maindrault-Goebel F, Chibaudel B, Formento JL, Francoual M, Lledo
G, André T, Mabro M, Mineur L, et al: Methylenetetrahydrofolate
reductase (MTHFR) gene polymorphisms and FOLFOX response in
colorectal cancer patients. Br J Clin Pharmacol. 69:58–66. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jakobsen A, Nielsen JN, Gyldenkerne N and
Lindeberg J: Thymidylate synthase and methylenetetrahydrofolate
reductase gene polymorphism in normal tissue as predictors of
fluorouracil sensitivity. J Clin Oncol. 23:1365–1369. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cohen V, Panet-Raymond V, Sabbaghian N,
Morin I, Batist G and Rozen R: Methylenetetrahydrofolate reductase
polymorphism in advanced colorectal cancer: A novel genomic
predictor of clinical response to fluoropyrimidine-based
chemotherapy. Clin Cancer Res. 9:1611–1615. 2003.PubMed/NCBI
|
|
27
|
Castillo-Fernández O, Santibáñez M, Bauza
A, Calderillo G, Castro C, Herrera R, Serrano A, Arrieta O and
Herrera LA: Methylenetetrahydrofolate reductase polymorphism (677
C>T) predicts long time to progression in metastatic colon
cancer treated with 5-fluorouracil and folinic acid. Arch Med Res.
41:430–435. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Suh KW, Kim JH, Kim DY, Kim YB, Lee C and
Choi S: Which gene is a dominant predictor of response during
FOLFOX chemotherapy for the treatment of metastatic colorectal
cancer, the MTHFR or XRCC1 gene? Ann Surg Oncol. 13:1379–1385.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Marcuello E, Altés A, Menoyo A, Rio ED and
Baiget M: Methylenetetrahydrofolate reductase gene polymorphisms:
Genomic predictors of clinical response to fluoropyrimidine-based
chemotherapy? Cancer Chemother Pharmacol. 57:835–840. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Derwinger K, Wettergren Y, Odin E,
Carlsson G and Gustavsson B: A study of the MTHFR gene polymorphism
C677T in colorectal cancer. Clin Colorectal Cancer. 8:43–48. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Sharma R, Hoskins JM, Rivory LP, Zucknick
M, London R, Liddle C and Clarke SJ: Thymidylate synthase and
methylenetetrahydrofolate reductase gene polymorphisms and toxicity
to capecitabine in advanced colorectal cancer patients. Clin Cancer
Res. 14:817–825. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wu H, Xu C, Chen G and Wang J: X-ray
repair cross-complementing 1 polymorphism and prognosis of
platinum-based chemotherapy in gastric and colorectal cancer: A
meta-analysis. J Gastroenterol Hepatol. 29:926–933. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Liang J, Jiang T, Yao RY, Liu ZM, Lv HY
and Qi WW: The combination of ERCC1 and XRCC1 gene polymorphisms
better predicts clinical outcome to oxaliplatin-based chemotherapy
in metastatic colorectal cancer. Cancer Chemother Pharmacol.
66:493–500. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ye F, Liu Z, Tan A, Liao M, Mo Z and Yang
X: XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based
chemotherapy in colorectal cancer: A meta-analysis. Cancer
Chemother Pharmacol. 71:733–740. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Lv H, Li Q, Qiu W, Xiang J, Wei H, Liang
H, Sui A and Liang J: Genetic polymorphism of XRCC1 correlated with
response to oxaliplatin-based chemotherapy in advanced colorectal
cancer. Pathol Oncol Res. 18:1009–1014. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Huang MY, Huang ML, Chen MJ, Lu CY, Chen
CF, Tsai PC, Chuang SC, Hou MF, Lin SR and Wang JY: Multiple
genetic polymorphisms in the prediction of clinical outcome of
metastatic colorectal cancer patients treated with first-line
FOLFOX-4 chemotherapy. Pharmacogenet Genomics. 21:18–25. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kawakami K and Watanabe G: Identification
and functional analysis of single nucleotide polymorphism in the
tandem repeat sequence of thymidylate synthase gene. Cancer Res.
63:6004–6007. 2003.PubMed/NCBI
|
|
39
|
Ruzzo A, Graziano F, Kawakami K, Watanabe
G, Santini D, Catalano V, Bisonni R, Canestrari E, Ficarelli R,
Menichetti ET, et al: Pharmacogenetic profiling and clinical
outcome of patients with advanced gastric cancer treated with
palliative chemotherapy. J Clin Oncol. 24:1883–1891. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sohn KJ, Croxford R, Yates Z, Lucock M and
Kim YI: Effect of the methylenetetrahydrofolate reductase C677T
polymorphism on chemosensitivity of colon and breast cancer cells
to 5-fluorouracil and methotrexate. J Natl Cancer Inst. 96:134–144.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Kawakami K, Omura K, Kanehira E and
Watanabe G: Methylenetetrahydrofolate reductase polymorphism is
associated with folate pool in gastrointestinal cancer tissue.
Anticancer Res. 21:285–289. 2001.PubMed/NCBI
|
|
42
|
Mohrenweiser HW, Xi T, Vázquez-Matías J
and Jones IM: Identification of 127 amino acid substitution
variants in screening 37 DNA repair genes in humans. Cancer
Epidemiol Biomarkers Prev. 11:1054–1064. 2002.PubMed/NCBI
|
|
43
|
Marusyk A and Polyak K: Tumor
heterogeneity: Causes and consequences. Biochim Biophys Acta.
1805:105–117. 2010.PubMed/NCBI
|
|
44
|
Giessen C, Laubender RP, von Weikersthal L
Fischer, Schalhorn A, Modest DP, Stintzing S, Haas M, Mansmann UR
and Heinemann V: Early tumor shrinkage in metastatic colorectal
cancer: Retrospective analysis from an irinotecan-based randomized
first-line trial. Cancer Sci. 104:718–724. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Heinemann V, Modest D, von Weikersthal LF,
Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T,
Lerchenmüller C, Kahl C, et al: Independent radiological evaluation
of objective response, early tumor shrinkage and depth of response
in FIRE-3 (AIO KRK-0306). Annals Oncol. 25:ii1172014. View Article : Google Scholar
|
|
46
|
Cui LH, Shin MH, Kweon SS, Kim HN, Song
HR, Piao JM, Choi JS, Shim HJ, Hwang JE, Kim HR, et al:
Methylenetetrahydrofolate reductase C677T polymorphism in patients
with gastric and colorectal cancer in a Korean population. BMC
Cancer. 10:2362010. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kim HN, Kim NY, Yu L, Kim YK, Lee IK, Yang
DH, Lee JJ, Shin MH, Park KS, Choi JS and Kim HJ: Polymorphisms of
drug-metabolizing genes and risk of non-Hodgkin lymphoma. Am J
Hematol. 84:821–825. 2009. View Article : Google Scholar : PubMed/NCBI
|
